articleThe LancetDec 21, 2010Closed access

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Hospices Civils de Lyon · Centre National de la Recherche Scientifique · +33 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

No related works found for this paper.